The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)
Bartosz Wasąg, Peter Vandenberghe(KU Leuven)
Cited by 61
Related Papers
Validation of a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations
|Diagnostic Pathology|2015|7